SCHEMBL5361463

SCHEMBL5361463

CCOC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(S(N)(=O)=O)cc32)c1C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 8/20 0.69
PDGFRB P09619 7/20 0.69
ALK Q9UM73 3/20 0.69
RET P07949 3/20 0.69
FLT3 P36888 3/20 0.69
ABL1 P00519 2/20 0.69
KDR P35968 12/20 0.66
EGFR P00533 5/20 0.66
PRKAA1 Q13131 4/20 0.51
PRKAA2 P54646 3/20 0.51
TLK2 Q86UE8 2/20 0.51
LRRK2 Q5S007 2/20 0.51
MET P08581 4/20 0.50
CSF1R P07333 3/20 0.50
SRC P12931 3/20 0.49
PTK2B Q14289 3/20 0.49
PLK4 O00444 2/20 0.49
DCLK1 O15075 2/20 0.49
PDPK1 O15530 2/20 0.49
DAPK3 O43293 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31727096 0.86 PDGFRB (0.74) FGFR1PDGFRBALKRETFLT3
SCHEMBL19255670 0.86 PDGFRB (0.77) FGFR1PDGFRBALKRETFLT3
SCHEMBL6389508 0.85 SRC (0.64) FGFR1PDGFRBALKRETFLT3
SCHEMBL6389502 0.85 SRC (0.64) FGFR1PDGFRBALKRETFLT3
SCHEMBL5373629 0.85 PDGFRB (0.76) FGFR1PDGFRBALKRETFLT3
SCHEMBL5363073 0.85 PDGFRB (0.71) FGFR1PDGFRBALKRETFLT3
SCHEMBL31726848 0.84 PDGFRB (0.74) FGFR1PDGFRBALKRETFLT3
SCHEMBL5376617 0.84 PDGFRB (0.74) FGFR1PDGFRBALKRETFLT3
SCHEMBL5392303 0.84 PDGFRB (0.74) FGFR1PDGFRBALKRETFLT3
SCHEMBL5567713 0.84 ALK (0.76) FGFR1PDGFRBALKRETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK FGFR1 112/4885PDGFRB 52/4885ALK 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.